STAT3-Mediated Signaling Dysregulates Lung Fibroblast-Myofibroblast Activation and Differentiation in UIP/IPF
STAT3 is a latent transcription factor that plays a role in regulating fibroblast function in fibrotic lung diseases. To further understand the role of STAT3 in the phenotypic divergence and function of human lung fibroblasts (LFs), we investigated the effect of basal and cytokine-induced STAT3 activity on indices of LF differentiation and activation, including expression of α-smooth muscle actin (α-SMA), collagen, and adhesion molecules Thy-1/CD90 and αv β3 and β5 integrins. We identified a population of fibroblasts from usual interstitial pneumonia (UIP)/idiopathic pulmonary fibrosis (IPF) lungs characterized by constitutively phosphorylated STAT3, lower proliferation rates, and diminished expression of α-SMA, Thy-1/CD90, and β3 integrins compared with control LFs. Staining of UIP lung biopsy specimens demonstrated that phosphorylated STAT3 was not present in α-SMA–positive fibroblastic foci but was observed in the nuclei of cells located in the areas of dense fibrosis. STAT3 activation in LFs did not significantly influence basal or transforming growth factor β1–induced collagen I expression but inhibited expression of α-SMA, Thy-1/CD90, and αv β3 integrins. Suppression of STAT3 signaling diminished resistance of IPF LFs to staurosporine-induced apoptosis and responsiveness to transforming growth factor β1 but increased basal α-SMA and restored β3 integrin expression in LFs via an ALK-5–dependent, SMAD3/7-independent mechanism. These data suggest that STAT3 activation regulates several pathways in human LFs associated with normal wound healing, whereas aberrant STAT3 signaling plays a critical role in UIP/IPF pathogenesis.
To access this article, please choose from the options below
Supported by Canadian Institutes for Health Research (MOP-97993), the British Columbia Lung Association, the Wolfe and Gita Churg Foundation, the Rashpal Dhillon endowment for IPF Research, and the National Health and Medical Research Council of Australia (project grant 303137). D.A.K. is the Canada Research Chair in Airway Disease and is a Career Investigator at the Michael Smith Foundation for Health Research.
Supplemental material for this article can be found at http://ajp.amjpathol.org and at doi: 10.1016/j.ajpath.2011.12.022.
PII: S0002-9440(12)00025-9
doi:10.1016/j.ajpath.2011.12.022
© 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
